Evidence map›Paper›PMID 29381697›Full record

ArticlePloS one2018

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.

Kelly Safreed-Harmon, Kristina L Hetherington, Soo Aleman, Hannu Alho, Olav Dalgard, Tove Frisch, Magnus Gottfredsson, Nina Weis, Jeffrey V Lazarus, Hep-Nordic Study Group

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Kelly Safreed-HarmonCHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Kristina L HetheringtonBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Soo AlemanDepartment of Infectious Diseases, Karolinska Institutet/Karolinska University Hospital, Stockholm, Sweden.
Hannu AlhoAbdominal Center, Helsinki University Hospital, Helsinki, Finland.
Olav DalgardDepartment of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway.
Tove FrischRiksföreningen Hepatit C, Månkarbo, Sweden.
Magnus GottfredssonFaculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Nina WeisDepartment of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Jeffrey V LazarusCHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-9618-2299
Hep-Nordic Study Group
University of Copenhagen · DKAkershus University Hospital · NOBarcelona Institute for Global Health · ESHelsinki University Hospital · FIKarolinska University Hospital · SEReykjavík University · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIn the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.

methodsFourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.

resultsStakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.

conclusionThe Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.

Indexed as

Cross-Sectional StudiesHepatitis CHumansPrevalencePublic Health PracticeScandinavian and Nordic CountriesSubstance Abuse, Intravenous

Identifiers

PMID29381697
PMCPMC5790214
OpenAlexW2788610058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.